- -------------------------------------------------------------------------
- -------------------------------------------------------------------------
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 1997
-----------------
SEROLOGICALS CORPORATION
- --------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-26126 58-2152225
- --------------------------------------------------------------------------
(State of other (Commission file number) (IRS Employer
Jurisdiction) Identification No.)
780 Park North Blvd.
Suite 110
Clarkston, Georgia 30021
- --------------------------------------------------------------------------
(Address of Principal executive offices) (Zip code)
Registrant's telephone number, including area code: (404) 296-5595
--------------
(Former name or former address, if changed since last report)
- -------------------------------------------------------------------------
- -------------------------------------------------------------------------
Item 5. Other Events
On September 10, 1997, Serologicals Corporation (the "Company")
issued a press release, attached hereto as Exhibit 99.1, to announce that
it had completed the sale of 950,000 shares of its common stock in a
private placement transaction. The Company also announced that one of its
stockholders had sold an additional 250,000 shares of the Company's common
stock owned by such stockholder pursuant to the same transaction.
Item 7. Financial Statements and Exhibits
a) Exhibits
99.1 Press Release of the Company dated September 10, 1997
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Serologicals Corporation
(Registrant)
Date: September 12, 1997 By: /s/ Russell H. Plumb//
--------------------------------
Russell H. Plumb
Vice President/Chief Financial
Officer (Principal Financial and
Accounting Officer)
NEWS
FOR IMMEDIATE RELEASE
Contact: Russell H. Plumb
Chief Financial Officer
(404) 296-5595
SEROLOGICALS COMPLETES PRIVATE PLACEMENT
OF 950,000 SHARES OF COMMON STOCK
ATLANTA, GA (September 10, 1997) - Serologicals Corporation (Nasdaq/NM:
SERO) today announced that is has completed the previously announced
private placement of 950,000 shares of its common stock at a purchase price
of $19.50 per share. The transaction also included the sale by a selling
stockholder of an additional 250,000 shares. The Company did not receive
any of the proceeds of the sale by the selling stockholder.
Serologicals intends to use the net proceeds of approximately $17.5
million for general corporate purposes, including strategic acquisitions or
investments.
The shares sold by the Company were not registered under the
Securities Act of 1933, as amended, pursuant to an exemption from the
registration requirements of the Securities Act. Such shares may not be
offered or sold in the United States absent registration or an applicable
exemption from the registration requirements of the Securities Act. A
registration statement relating to the resale by the purchasers of the
shares of common stock sold by the Company was declared effective by the
Securties and Exchange Commission on September 3, 1997.
Serologicals Corporation, headquartered in Atlanta, Georgia, is a
leading worldwide provider of specialty human antibody-based products and
services to major heathcare companies. The Company's services, including
donor recruitment, donor management and clinical testing services, enable
the Company to provide value-added products that are used as the active
ingredients in therapeutic products for the treatment and management of
such medical indications as Rh incompatibility in newborns, rabies and
hepatitis and in diagnostic products such as blood typing reagents and
diagnostic test kits.
This release may contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including the
intended use of the net proceeds received from the private placement.
These forward-looking statements are subject to certain risks,
uncertainties and other factors, such as the ability to identify, acquire
and integrate acquisition targets, which could cause actual results to
differ materially. Additional information on factors that could
potentially affect the Company or its financial results may be found in the
Company's filings with the Securities and Exchange Commission.
-END-
